|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07H 19/073 | |
| C07H 19/10 | |||
| C07H 21/04 | |||
| C12N 15/115 |
| (11) | Patento numeris | 2558586 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11769393.7 |
| Europos patento paraiškos padavimo data | 2011-04-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-02-20 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-10-12 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/032017 |
| Data | 2011-04-12 |
| (87) | Numeris | WO 2011/130195 |
| Data | 2011-10-20 |
| (30) | Numeris | Data | Šalis |
| 323145 P | 2010-04-12 | US |
| (72) |
SCHNEIDER, Daniel, J., US
HISAMINATO, Akihiko, JP
WAUGH, Sheela, US
RESNICOW, Daniel, US
NAGABUKURO, Akira, JP
ONO, Toshihide, JP
|
| (73) |
Otsuka Pharmaceutical Co., Limited,
2-9, Kanda-Tsukasamachi, Chiyoda-ku Tokyo 101-8535,
JP
Somalogic, Inc., 2945 Wilderness Place, Boulder, CO 80301, US |
| (54) | APTAMERS TO -NGF AND THEIR USE IN TREATING -NGF MEDIATED DISEASES AND DISORDERS |
| APTAMERS TO -NGF AND THEIR USE IN TREATING -NGF MEDIATED DISEASES AND DISORDERS |